Merrion Pharmaceuticals, Inc. Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk A/S

DUBLIN, Ireland, July 18, 2008 (PRIME NEWSWIRE) -- Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing.